{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T16:07:41Z","timestamp":1793549261704,"version":"4.5.0"},"reference-count":181,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biology"],"abstract":"<jats:p>Interleukin-23 is crucial in the initiation and progression of certain inflammatory disorders. As a key cytokine, IL-23 is involved in the differentiation and activation of Th17 cells, which play a role in a broad spectrum of inflammatory diseases. This review examines the molecular mechanisms through which IL-23 contributes to the pathogenesis of conditions including psoriasis, rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. By elucidating the significant role of IL-23 in inflammation, this review underscores its importance as a therapeutic target for managing inflammatory conditions, with particular emphasis on current and emerging biologic treatments.<\/jats:p>","DOI":"10.3390\/biology14040347","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:36:48Z","timestamp":1743136608000},"page":"347","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["The Role of IL-23 in the Development of Inflammatory Diseases"],"prefix":"10.3390","volume":"14","author":[{"given":"Mario","family":"Garc\u00eda-Dom\u00ednguez","sequence":"first","affiliation":[{"name":"Program of Immunology and Immunotherapy, CIMA-Universidad de Navarra, 31008 Pamplona, Spain"},{"name":"Department of Immunology and Immunotherapy, Cl\u00ednica Universidad de Navarra, 31008 Pamplona, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer (CIBERONC), 28029 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nature07201","article-title":"Origin and physiological roles of inflammation","volume":"454","author":"Medzhitov","year":"2008","journal-title":"Nature"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1126\/science.abi5200","article-title":"The spectrum of inflammatory responses","volume":"374","author":"Medzhitov","year":"2021","journal-title":"Science"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1610136","DOI":"10.3389\/pore.2021.1610136","article-title":"Inflammation in Focus: The Beginning and the End","volume":"27","author":"Kiss","year":"2022","journal-title":"Pathol. Oncol. Res."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Soares, C.L.R., Wilairatana, P., Silva, L.R., Moreira, P.S., Vilar Barbosa, N.M.M., da Silva, P.R., Coutinho, H.D.M., de Menezes, I.R.A., and Felipe, C.F.B. (2023). Biochemical aspects of the inflammatory process: A narrative review. Biomed. Pharmacother., 168.","DOI":"10.1016\/j.biopha.2023.115764"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"17023","DOI":"10.1038\/sigtrans.2017.23","article-title":"NF-\u03baB signaling in inflammation","volume":"2","author":"Liu","year":"2017","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Kany, S., Vollrath, J.T., and Relja, B. (2019). Cytokines in Inflammatory Disease. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20236008"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Ch\u00e1vez-Castillo, M., Ortega, \u00c1., Cudris-Torres, L., Duran, P., Rojas, M., Manzano, A., Garrido, B., Salazar, J., Silva, A., and Rojas-Gomez, D.M. (2021). Specialized Pro-Resolving Lipid Mediators: The Future of Chronic Pain Therapy?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910370"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"101605","DOI":"10.1016\/j.smim.2022.101605","article-title":"Specialized pro-resolving mediators as modulators of immune responses","volume":"59","author":"Julliard","year":"2022","journal-title":"Semin. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nri.2015.4","article-title":"Specialized pro-resolving mediators: Endogenous regulators of infection and inflammation","volume":"16","author":"Basil","year":"2016","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"7204","DOI":"10.18632\/oncotarget.23208","article-title":"Inflammatory responses and inflammation-associated diseases in organs","volume":"9","author":"Chen","year":"2017","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1603990","DOI":"10.3389\/phrs.2021.1603990","article-title":"A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration","volume":"42","author":"Tavakoli","year":"2021","journal-title":"Public Health Rev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e509","DOI":"10.1002\/mco2.509","article-title":"Rheumatoid arthritis: Pathogenesis and therapeutic advances","volume":"5","author":"Gao","year":"2024","journal-title":"MedComm"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e37297","DOI":"10.1097\/MD.0000000000037297","article-title":"Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment","volume":"103","author":"Haki","year":"2024","journal-title":"Medicine"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Szewczak, L., and Donskow-\u0141ysoniewska, K. (2020). Cytokines and Transgenic Matrix in Autoimmune Diseases: Similarities and Differences. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120559"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Yasmeen, F., Pirzada, R.H., Ahmad, B., Choi, B., and Choi, S. (2024). Understanding Autoimmunity: Mechanisms, Predisposing Factors, and Cytokine Therapies. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25147666"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1089\/jir.2011.0065","article-title":"Cytokines in autoimmunity: Role in induction, regulation, and treatment","volume":"31","author":"Moudgil","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00011-020-01339-9","article-title":"Interleukin 23 and autoimmune diseases: Current and possible future therapies","volume":"69","author":"Abdo","year":"2020","journal-title":"Inflamm. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100261","DOI":"10.1016\/j.xjidi.2024.100261","article-title":"Structural Basis for p19 Targeting by Anti-IL-23 Biologics: Correlations with Short- and Long-Term Efficacy in Psoriasis","volume":"4","author":"Daniele","year":"2024","journal-title":"JID Innov."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Floss, D.M., Moll, J.M., and Scheller, J. (2020). IL-12 and IL-23-Close Relatives with Structural Homologies but Distinct Immunological Functions. Cells, 9.","DOI":"10.3390\/cells9102184"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.cyto.2019.02.018","article-title":"IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy?","volume":"120","author":"Li","year":"2019","journal-title":"Cytokine"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bunte, K., and Beikler, T. (2019). Th17 Cells and the IL-23\/IL-17 Axis in the Pathogenesis of Periodontitis and Immune-Mediated Inflammatory Diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20143394"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/s41577-021-00596-x","article-title":"Defining the TH17 cell lineage","volume":"21","author":"Dong","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"102333","DOI":"10.1016\/j.coi.2023.102333","article-title":"TH17 cell immune adaptation","volume":"83","author":"Agalioti","year":"2023","journal-title":"Curr. Opin. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Krueger, J.G., Eyerich, K., Kuchroo, V.K., Ritchlin, C.T., Abreu, M.T., Elloso, M.M., Fourie, A., Fakharzadeh, S., Sherlock, J.P., and Yang, Y.W. (2024). IL-23 past, present, and future: A roadmap to advancing IL-23 science and therapy. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1331217"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Zhang, W., Zhong, G., Ren, X., and Li, M. (2024). Research progress of Ustekinumab in the treatment of inflammatory bowel disease. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1322054"},{"key":"ref_26","first-page":"e51405","article-title":"Guselkumab, a Novel Monoclonal Antibody Inhibitor of the p19 Subunit of IL-23, for Psoriatic Arthritis and Plaque Psoriasis: A Review of Its Mechanism, Use, and Clinical Effectiveness","volume":"15","author":"Kerut","year":"2023","journal-title":"Cureus"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5114\/reum.2019.86426","article-title":"Risankizumab in the treatment of psoriasis\u2014Literature review","volume":"57","author":"Banaszczyk","year":"2019","journal-title":"Reumatologia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mirlekar, B., and Pylayeva-Gupta, Y. (2021). IL-12 Family Cytokines in Cancer and Immunotherapy. Cancers, 13.","DOI":"10.3390\/cancers13020167"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Hasegawa, H., Mizoguchi, I., Chiba, Y., Ohashi, M., Xu, M., and Yoshimoto, T. (2016). Expanding Diversity in Molecular Structures and Functions of the IL-6\/IL-12 Heterodimeric Cytokine Family. Front. Immunol., 7.","DOI":"10.3389\/fimmu.2016.00479"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/j.jmb.2008.07.051","article-title":"The structure of interleukin-23 reveals the molecular basis of p40 subunit sharing with interleukin-12","volume":"382","author":"Lupardus","year":"2008","journal-title":"J. Mol. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.immuni.2017.12.008","article-title":"Structural Activation of Pro-inflammatory Human Cytokine IL-23 by Cognate IL-23 Receptor Enables Recruitment of the Shared Receptor IL-12R\u03b21","volume":"48","author":"Bloch","year":"2018","journal-title":"Immunity"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/icb.2016.93","article-title":"Distinctive expression of interleukin-23 receptor subunits on human Th17 and \u03b3\u03b4 T cells","volume":"95","author":"Wines","year":"2017","journal-title":"Immunol. Cell Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cyto.2014.11.018","article-title":"IL12R\u03b21: The cytokine receptor that we used to know","volume":"71","author":"Robinson","year":"2015","journal-title":"Cytokine"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Pastor-Fern\u00e1ndez, G., Mariblanca, I.R., and Navarro, M.N. (2020). Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities. Cells, 9.","DOI":"10.3390\/cells9092044"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s13238-018-0505-z","article-title":"IL-23-induced macrophage polarization and its pathological roles in mice with imiquimod-induced psoriasis","volume":"9","author":"Hou","year":"2018","journal-title":"Protein Cell."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5167","DOI":"10.4049\/jimmunol.180.8.5167","article-title":"Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion","volume":"180","author":"Rachitskaya","year":"2008","journal-title":"J. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/mi.2014.77","article-title":"IL-23 activates innate lymphoid cells to promote neonatal intestinal pathology","volume":"8","author":"Chen","year":"2015","journal-title":"Mucosal Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"eaaw0402","DOI":"10.1126\/sciimmunol.aaw0402","article-title":"IL-23 costimulates antigen-specific MAIT cell activation and enables vaccination against bacterial infection","volume":"4","author":"Wang","year":"2019","journal-title":"Sci. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.cell.2021.01.018","article-title":"Structural basis for IL-12 and IL-23 receptor sharing reveals a gateway for shaping actions on T versus NK cells","volume":"184","author":"Glassman","year":"2021","journal-title":"Cell"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1089\/jir.2010.0083","article-title":"Interleukin-23-induced interleukin-23 receptor subunit expression is mediated by the Janus kinase\/signal transducer and activation of transcription pathway in human CD4\u2009T cells","volume":"31","author":"Zhang","year":"2011","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ccr.2008.12.018","article-title":"Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment","volume":"15","author":"Kortylewski","year":"2009","journal-title":"Cancer Cell"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e91663","DOI":"10.1172\/jci.insight.91663","article-title":"IL-23R-activated STAT3\/STAT4 is essential for Th1\/Th17-mediated CNS autoimmunity","volume":"2","author":"Lee","year":"2017","journal-title":"JCI Insight"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1093\/rheumatology\/kead022","article-title":"ROR\u03b3t inhibition ameliorates IL-23 driven experimental psoriatic arthritis by predominantly modulating \u03b3\u03b4-T cells","volume":"62","author":"Mortier","year":"2023","journal-title":"Rheumatology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/bs.ircmb.2017.07.007","article-title":"NF-\u03baB and the Transcriptional Control of Inflammation","volume":"335","author":"Mitchell","year":"2018","journal-title":"Int. Rev. Cell Mol. Biol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Liu, D., Zhong, Z., and Karin, M. (2022). NF-\u03baB: A Double-Edged Sword Controlling Inflammation. Biomedicines, 10.","DOI":"10.3390\/biomedicines10061250"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-024-01757-9","article-title":"NF-\u03baB in biology and targeted therapy: New insights and translational implications","volume":"9","author":"Guo","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Liu, P., Li, Y., Wang, W., Bai, Y., Jia, H., Yuan, Z., and Yang, Z. (2022). Role and mechanisms of the NF-\u0138B signaling pathway in various developmental processes. Biomed. Pharmacother., 153.","DOI":"10.1016\/j.biopha.2022.113513"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Barnabei, L., Laplantine, E., Mbongo, W., Rieux-Laucat, F., and Weil, R. (2021). NF-\u03baB: At the Borders of Autoimmunity and Inflammation. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.716469"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/jid.2010.432","article-title":"IL-23-mediated epidermal hyperplasia is dependent on IL-6","volume":"131","author":"Lindroos","year":"2011","journal-title":"J. Investig. Dermatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.4049\/jimmunol.0902796","article-title":"IL-23 receptor regulates unconventional IL-17-producing T cells that control bacterial infections","volume":"184","author":"Lazarevic","year":"2010","journal-title":"J. Immunol."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Bhattacharya, G., Sengupta, S., Jha, R., Shaw, S.K., Jogdand, G.M., Barik, P.K., Padhan, P., Parida, J.R., and Devadas, S. (2023). IL-21\/23 axis modulates inflammatory cytokines and RANKL expression in RA CD4+ T cells via p-Akt1 signaling. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1235514"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cell.2015.08.061","article-title":"An IL-23R\/IL-22 Circuit Regulates Epithelial Serum Amyloid A to Promote Local Effector Th17 Responses","volume":"163","author":"Sano","year":"2015","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1089\/jir.2014.0149","article-title":"Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy","volume":"35","author":"Bhattacharya","year":"2015","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e12946","DOI":"10.1111\/sji.12946","article-title":"The TNF\/IL-23\/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment","volume":"92","author":"Petrovic","year":"2020","journal-title":"Scand. J. Immunol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Korta, A., Kula, J., and Gomu\u0142ka, K. (2023). The Role of IL-23 in the Pathogenesis and Therapy of Inflammatory Bowel Disease. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241210172"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.intimp.2017.03.001","article-title":"Interleukin-23 mediates the pathogenesis of LPS\/GalN-induced liver injury in mice","volume":"46","author":"Bao","year":"2017","journal-title":"Int. Immunopharmacol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1111\/jdv.19328","article-title":"Evaluating the risk of infections under interleukin 23 and interleukin 17 inhibitors relative to tumour necrosis factor inhibitors\u2014A population-based study","volume":"37","author":"Kridin","year":"2023","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1182\/blood-2008-08-175448","article-title":"Interleukin-23 secretion by donor antigen-presenting cells is critical for organ-specific pathology in graft-versus-host disease","volume":"113","author":"Das","year":"2009","journal-title":"Blood"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.molimm.2006.09.001","article-title":"TLR-ligand stimulated interleukin-23 subunit expression and assembly is regulated differentially in murine plasmacytoid and myeloid dendritic cells","volume":"44","author":"Waibler","year":"2007","journal-title":"Mol. Immunol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1038\/cmi.2017.39","article-title":"Characterization and biological significance of IL-23-induced neutrophil polarization","volume":"15","author":"Li","year":"2018","journal-title":"Cell. Mol. Immunol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41586-024-07537-3","article-title":"CTLA-4-expressing ILC3s restrain interleukin-23-mediated inflammation","volume":"630","author":"Ahmed","year":"2024","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/s41423-024-01183-5","article-title":"HIF-1\u03b1 and MIF enhance neutrophil-driven type 3 immunity and chondrogenesis in a murine spondyloarthritis model","volume":"21","author":"Nakamura","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6723","DOI":"10.1038\/s41467-022-34532-x","article-title":"CD1d-dependent rewiring of lipid metabolism in macrophages regulates innate immune responses","volume":"13","author":"Brailey","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/s41467-018-03704-z","article-title":"Epigenetic control of IL-23 expression in keratinocytes is important for chronic skin inflammation","volume":"9","author":"Li","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.immuni.2015.08.016","article-title":"Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity","volume":"43","author":"Kashem","year":"2015","journal-title":"Immunity"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1038\/jid.2014.98","article-title":"IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing \u03b3\u03b4 T cells","volume":"134","author":"Yoshiki","year":"2014","journal-title":"J. Investig. Dermatol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1002\/art.24389","article-title":"Overexpression of interleukin-23, but not interleukin-17, as an immunologic signature of subclinical intestinal inflammation in ankylosing spondylitis","volume":"60","author":"Ciccia","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e16427","DOI":"10.15252\/emmm.202216427","article-title":"Paneth cells as the cornerstones of intestinal and organismal health: A primer","volume":"15","author":"Wallaeys","year":"2023","journal-title":"EMBO Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Noviello, D., Mager, R., Roda, G., Borroni, R.G., Fiorino, G., and Vetrano, S. (2021). The IL23-IL17 Immune Axis in the Treatment of Ulcerative Colitis: Successes, Defeats, and Ongoing Challenges. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.611256"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.mucimm.2024.05.008","article-title":"IL-23 exerts dominant pathogenic functions in Crohn\u2019s disease-ileitis","volume":"17","author":"Iliopoulou","year":"2024","journal-title":"Mucosal Immunol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41590-022-01387-9","article-title":"TH17 cell heterogeneity and its role in tissue inflammation","volume":"24","author":"Schnell","year":"2023","journal-title":"Nat. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"5948","DOI":"10.4049\/jimmunol.181.9.5948","article-title":"IL-23 promotes maintenance but not commitment to the Th17 lineage","volume":"181","author":"Stritesky","year":"2008","journal-title":"J. Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/imm.12938","article-title":"The role of transforming growth factor \u03b2 in T helper 17 differentiation","volume":"155","author":"Zhang","year":"2018","journal-title":"Immunology"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Pan, Y., Yang, W., Tang, B., Wang, X., Zhang, Q., Li, W., and Li, L. (2023). The protective and pathogenic role of Th17 cell plasticity and function in the tumor microenvironment. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1192303"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1089\/jir.2018.0057","article-title":"IL-17, IL-21, and IL-22 Cytokines of T Helper 17 Cells in Cancer","volume":"39","author":"Nalbant","year":"2019","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Chyuan, I.T., and Lai, J.H. (2020). New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem. Pharmacol., 175.","DOI":"10.1016\/j.bcp.2020.113928"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/978-3-030-55617-4_6","article-title":"IL-23 and the Tumor Microenvironment","volume":"1290","author":"Subhadarshani","year":"2021","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/CJI.0b013e3182a802cf","article-title":"IL-17A promotes immune cell recruitment in human esophageal cancers and the infiltrating dendritic cells represent a positive prognostic marker for patient survival","volume":"36","author":"Lu","year":"2013","journal-title":"J. Immunother."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/mi.2016.80","article-title":"IL-17A-mediated neutrophil recruitment limits expansion of segmented filamentous bacteria","volume":"10","author":"Flannigan","year":"2017","journal-title":"Mucosal Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"8887","DOI":"10.1158\/0008-5472.CAN-05-3448","article-title":"Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells","volume":"66","author":"Hu","year":"2006","journal-title":"Cancer Res."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.7150\/thno.56494","article-title":"Intratumoral expression of interleukin 23 variants using oncolytic vaccinia virus elicit potent antitumor effects on multiple tumor models via tumor microenvironment modulation","volume":"11","author":"Chen","year":"2021","journal-title":"Theranostics"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Yan, J., Smyth, M.J., and Teng, M.W.L. (2018). Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer. Cold Spring Harb. Perspect. Biol., 10.","DOI":"10.1101\/cshperspect.a028530"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e20190297","DOI":"10.1084\/jem.20190297","article-title":"The role of interleukin-17 in tumor development and progression","volume":"217","author":"Zhao","year":"2020","journal-title":"J. Exp. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1758606","DOI":"10.1080\/2162402X.2020.1758606","article-title":"IL-17 suppresses the therapeutic activity of cancer vaccines through the inhibition of CD8+ T-cell responses","volume":"9","author":"Dadaglio","year":"2020","journal-title":"Oncoimmunology"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"623759","DOI":"10.1155\/2014\/623759","article-title":"The role of interleukin 17 in tumour proliferation, angiogenesis, and metastasis","volume":"2014","author":"Yang","year":"2014","journal-title":"Mediators Inflamm."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1182\/blood-2002-05-1461","article-title":"Interleukin-17 promotes angiogenesis and tumor growth","volume":"101","author":"Numasaki","year":"2003","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Huang, Q., Duan, L., Qian, X., Fan, J., Lv, Z., Zhang, X., Han, J., Wu, F., Guo, M., and Hu, G. (2016). IL-17 Promotes Angiogenic Factors IL-6, IL-8, and Vegf Production via Stat1 in Lung Adenocarcinoma. Sci. Rep., 6.","DOI":"10.1038\/srep36551"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/s41590-024-01755-7","article-title":"IL-23 stabilizes an effector Treg cell program in the tumor microenvironment","volume":"25","author":"Wertheimer","year":"2024","journal-title":"Nat. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"5894","DOI":"10.4049\/jimmunol.1203141","article-title":"Increased Th17 cells in the tumor microenvironment is mediated by IL-23 via tumor-secreted prostaglandin E2","volume":"190","author":"Qian","year":"2013","journal-title":"J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41586-018-0266-0","article-title":"IL-23 secreted by myeloid cells drives castration-resistant prostate cancer","volume":"559","author":"Calcinotto","year":"2018","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.immuni.2023.01.004","article-title":"Principles of regulatory T cell function","volume":"56","author":"Dikiy","year":"2023","journal-title":"Immunity"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"968549","DOI":"10.1155\/2013\/968549","article-title":"Pivotal roles of T-helper 17-related cytokines, IL-17, IL-22, and IL-23, in inflammatory diseases","volume":"2013","author":"Qu","year":"2013","journal-title":"Clin. Dev. Immunol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s13075-024-03380-z","article-title":"The mode of action of IL-23 in experimental inflammatory arthritic pain and disease","volume":"26","author":"Lee","year":"2024","journal-title":"Arthritis Res. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13075-020-02212-0","article-title":"IL-23 in arthritic and inflammatory pain development in mice","volume":"22","author":"Lee","year":"2020","journal-title":"Arthritis Res. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13075-022-02777-y","article-title":"The role of interleukin (IL)-23 in regulating pain in arthritis","volume":"24","author":"Lee","year":"2022","journal-title":"Arthritis Res. Ther."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.joca.2024.05.011","article-title":"IL-23p19 in osteoarthritic pain and disease","volume":"32","author":"Lee","year":"2024","journal-title":"Osteoarthr. Cartil."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"iv4","DOI":"10.1093\/rheumatology\/keab266","article-title":"IL-23 orchestrating immune cell activation in arthritis","volume":"60","author":"Najm","year":"2021","journal-title":"Rheumatology"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/art.1780200714","article-title":"Zymosan-induced arthritis: A model of chronic proliferative arthritis following activation of the alternative pathway of complement","volume":"20","author":"Keystone","year":"1977","journal-title":"Arthritis Rheum."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1476-5381.2011.01302.x","article-title":"Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS)","volume":"164","author":"Constantinescu","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/ni.2031","article-title":"The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF","volume":"12","author":"Ciric","year":"2011","journal-title":"Nat. Immunol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bbi.2014.12.007","article-title":"Analysis of TGF-\u03b21 and TGF-\u03b23 as regulators of encephalitogenic Th17 cells: Implications for multiple sclerosis","volume":"46","author":"Lee","year":"2015","journal-title":"Brain Behav. Immun."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"a029637","DOI":"10.1101\/cshperspect.a029637","article-title":"The Interleukin (IL)-23\/T helper (Th)17 Axis in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis","volume":"8","author":"Hiltensperger","year":"2018","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"eabn7774","DOI":"10.1126\/sciadv.abn7774","article-title":"ROR\u03b3t expression in mature TH17 cells safeguards their lineage specification by inhibiting conversion to TH2 cells","volume":"8","author":"Chi","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"eabq3254","DOI":"10.1126\/sciimmunol.abq3254","article-title":"Local IL-23 is required for proliferation and retention of skin-resident memory TH17 cells","volume":"7","author":"Whitley","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"5836","DOI":"10.4049\/jimmunol.0802999","article-title":"Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23\/IL-17 axis","volume":"182","author":"Mourits","year":"2009","journal-title":"J. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4481","DOI":"10.4049\/jimmunol.1000148","article-title":"Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model","volume":"186","author":"Nakajima","year":"2011","journal-title":"J. Immunol."},{"key":"ref_107","first-page":"597","article-title":"IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation","volume":"118","author":"Ma","year":"2008","journal-title":"J. Clin. Investig."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s13555-021-00483-2","article-title":"Interleukin-17 and Interleukin-23: A Narrative Review of Mechanisms of Action in Psoriasis and Associated Comorbidities","volume":"11","author":"Menter","year":"2021","journal-title":"Dermatol. Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 Signaling Pathway and the Treatment of Psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J. Immunol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Schmitt, H., Neurath, M.F., and Atreya, R. (2021). Role of the IL23\/IL17 Pathway in Crohn\u2019s Disease. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.622934"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1074\/jbc.M111.304949","article-title":"Interleukin (IL)-23 suppresses IL-10 in inflammatory bowel disease","volume":"287","author":"Liu","year":"2012","journal-title":"J. Biol. Chem."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41423-024-01218-x","article-title":"Type 17 immunity: Novel insights into intestinal homeostasis and autoimmune pathogenesis driven by gut-primed T cells","volume":"21","author":"Ohara","year":"2024","journal-title":"Cell. Mol. Immunol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"8816041","DOI":"10.1155\/2021\/8816041","article-title":"Th17 Cells in Inflammatory Bowel Disease: Cytokines, Plasticity, and Therapies","volume":"2021","author":"Zhao","year":"2021","journal-title":"J. Immunol. Res."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Xu, W.D., Xie, Q.B., Zhao, Y., and Liu, Y. (2015). Association of Interleukin-23 receptor gene polymorphisms with susceptibility to Crohn\u2019s disease: A meta-analysis. Sci. Rep., 5.","DOI":"10.1038\/srep18584"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2007.02.051","article-title":"IL23R variation determines susceptibility but not disease phenotype in inflammatory bowel disease","volume":"132","author":"Tremelling","year":"2007","journal-title":"Gastroenterology"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1172\/JCI21404","article-title":"IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6","volume":"116","author":"Yen","year":"2006","journal-title":"J. Clin. Investig."},{"key":"ref_117","doi-asserted-by":"crossref","unstructured":"Ji, J., He, Q., Luo, X., Bang, S., Matsuoka, Y., McGinnis, A., Nackley, A.G., and Ji, R.R. (2021). IL-23 Enhances C-Fiber-Mediated and Blue Light-Induced Spontaneous Pain in Female Mice. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.787565"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.bbi.2013.12.011","article-title":"Up-regulation of interleukin-23 induces persistent allodynia via CX3CL1 and interleukin-18 signaling in the rat spinal cord after tetanic sciatic stimulation","volume":"37","author":"Bian","year":"2014","journal-title":"Brain Behav. Immun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1194\/jlr.R800042-JLR200","article-title":"Cyclooxygenases: Structural and functional insights","volume":"50","author":"Rouzer","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/156802607779941314","article-title":"Eicosanoids in inflammation: Biosynthesis, pharmacology, and therapeutic frontiers","volume":"7","author":"Khanapure","year":"2007","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12974-020-1703-1","article-title":"Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception","volume":"17","author":"Jang","year":"2020","journal-title":"J. Neuroinflamm."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Alderbi, R.M., Alam, M.Z., Alghamdi, B.S., Alsufiani, H.M., Abd El-Aziz, G.S., Omar, U.M., and Al-Ghamdi, M.A. (2025). Neurotherapeutic impact of vanillic acid and ibudilast on the cuprizone model of multiple sclerosis. Front. Mol. Neurosci., 17.","DOI":"10.3389\/fnmol.2024.1503396"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"60","DOI":"10.2174\/1573409919666230417103413","article-title":"Novel 1-H Phenyl Benzimidazole Derivatives for IBD Therapy\u2014An in-vitro and in-silico Approach to Evaluate its Effects on the IL-23 Mediated Inflammatory Pathway","volume":"20","author":"Vishnu","year":"2024","journal-title":"Curr. Comput. Aided Drug Des."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Arasa, J., Terencio, M.C., Andr\u00e9s, R.M., Mar\u00edn-Castej\u00f3n, A., Valcuende-Cavero, F., Pay\u00e1, M., and Montesinos, M.C. (2019). Defective Induction of COX-2 Expression by Psoriatic Fibroblasts Promotes Pro-inflammatory Activation of Macrophages. Front. Immunol., 10.","DOI":"10.3389\/fimmu.2019.00536"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.redox.2015.08.006","article-title":"The role of lipoxygenases in pathophysiology; new insights and future perspectives","volume":"6","author":"Mashima","year":"2015","journal-title":"Redox Biol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.immuni.2012.06.018","article-title":"Leukotriene B4-driven neutrophil recruitment to the skin is essential for allergic skin inflammation","volume":"37","author":"Oyoshi","year":"2012","journal-title":"Immunity"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1159\/000353694","article-title":"Leukotriene B4, an endogenous stimulator of the innate immune response against pathogens","volume":"6","author":"Brunet","year":"2014","journal-title":"J. Innate Immun."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s12990-015-0059-5","article-title":"Leukotriene enhances NMDA-induced inward currents in dorsal horn neurons of the rat spinal cord after peripheral nerve injury","volume":"11","author":"Kiyoyuki","year":"2015","journal-title":"Mol. Pain"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Asahara, M., Ito, N., Hoshino, Y., Sasaki, T., Yokomizo, T., Nakamura, M., Shimizu, T., and Yamada, Y. (2022). Role of leukotriene B4 (LTB4)-LTB4 receptor 1 signaling in post-incisional nociceptive sensitization and local inflammation in mice. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0276135"},{"key":"ref_130","first-page":"872","article-title":"Pain and bone damage in rheumatoid arthritis: Role of leukotriene B4","volume":"37","author":"Zheng","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s12974-023-02981-w","article-title":"Arachidonic acid-derived lipid mediators in multiple sclerosis pathogenesis: Fueling or dampening disease progression?","volume":"21","author":"Broos","year":"2024","journal-title":"J. Neuroinflamm."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Pietrantonio, F., Serreqi, A., Zerbe, H., Svenningsson, P., and Aigner, L. (2024). The leukotriene receptor antagonist montelukast as a potential therapeutic adjuvant in multiple sclerosis\u2014A review. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1450493"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainres.2004.06.045","article-title":"Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12\/15-lipoxygenase or 5-lipoxygenase","volume":"1021","author":"Emerson","year":"2004","journal-title":"Brain Res."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.plefa.2011.04.022","article-title":"Inhibition of 5-lipoxygenase activity in mice during cuprizone-induced demyelination attenuates neuroinflammation, motor dysfunction and axonal damage","volume":"85","author":"Yoshikawa","year":"2011","journal-title":"Prostaglandins Leukot. Essent. Fatty Acids"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/imm.13308","article-title":"Montelukast alleviates inflammation in experimental autoimmune encephalomyelitis by altering Th17 differentiation in a mouse model","volume":"163","author":"Han","year":"2021","journal-title":"Immunology"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/brain\/awl273","article-title":"Increased IL-23p19 expression in multiple sclerosis lesions and its induction in microglia","volume":"130","author":"Li","year":"2007","journal-title":"Brain"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ibd.20094","article-title":"Colonic expression of leukotriene-pathway enzymes in inflammatory bowel diseases","volume":"13","author":"Jupp","year":"2007","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1136\/gutjnl-2015-310705","article-title":"Proteomic analysis of ascending colon biopsies from a paediatric inflammatory bowel disease inception cohort identifies protein biomarkers that differentiate Crohn\u2019s disease from UC","volume":"66","author":"Starr","year":"2017","journal-title":"Gut"},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Zhang, C., Zhang, J., Zhang, Y., Song, Z., Bian, J., Yi, H., and Ma, Z. (2023). Identifying neutrophil-associated subtypes in ulcerative colitis and confirming neutrophils promote colitis-associated colorectal cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1095098"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1073\/pnas.95.12.6744","article-title":"A 12R-lipoxygenase in human skin: Mechanistic evidence, molecular cloning, and expression","volume":"95","author":"Boeglin","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.prostaglandins.2006.05.006","article-title":"Role of epidermis-type lipoxygenases for skin barrier function and adipocyte differentiation","volume":"82","author":"Epp","year":"2007","journal-title":"Prostaglandins Other Lipid Mediat."},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Bhuktar, H., Shukla, S., Kakularam, K.R., Battu, S., Srikanth, M., Srivastava, S., Medishetti, R., Ram, P., Jagadish, P.C., and Rasool, M. (2023). Design, synthesis and evaluation of 2-aryl quinoline derivatives against 12R-lipoxygenase (12R-LOX): Discovery of first inhibitor of 12R-LOX. Bioorg. Chem., 138.","DOI":"10.1016\/j.bioorg.2023.106606"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1146\/annurev.immunol.25.022106.141557","article-title":"IL-17 family cytokines and the expanding diversity of effector T cell lineages","volume":"25","author":"Weaver","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1016\/j.neuron.2021.06.015","article-title":"IL-23\/IL-17A\/TRPV1 axis produces mechanical pain via macrophage-sensory neuron crosstalk in female mice","volume":"109","author":"Luo","year":"2021","journal-title":"Neuron"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1159\/000354525","article-title":"IL-17A induces pro-inflammatory cytokines production in macrophages via MAPKinases, NF-\u03baB and AP-1","volume":"32","author":"Chen","year":"2013","journal-title":"Cell. Physiol. Biochem."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12264-021-00797-3","article-title":"The Macrophage IL-23\/IL-17A Pathway: A New Neuro-Immune Mechanism in Female Mechanical Pain","volume":"38","author":"Tan","year":"2022","journal-title":"Neurosci. Bull."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1111\/j.1365-2133.2010.10129.x","article-title":"Depletion of antigen-presenting cells by clodronate liposomes reverses the psoriatic skin phenotype in KC-Tie2 mice","volume":"164","author":"Ward","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Jiang, X., Zhou, R., Zhang, Y., Zhu, T., Li, Q., and Zhang, W. (2022). Interleukin-17 as a potential therapeutic target for chronic pain. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.999407"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1002\/art.37695","article-title":"Interleukin-17 sensitizes joint nociceptors to mechanical stimuli and contributes to arthritic pain through neuronal interleukin-17 receptors in rodents","volume":"64","author":"Richter","year":"2012","journal-title":"Arthritis Rheum."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1186\/s13075-014-0470-8","article-title":"Nociceptive neurons detect cytokines in arthritis","volume":"16","author":"Schaible","year":"2014","journal-title":"Arthritis Res. Ther."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.pain.2012.10.022","article-title":"Spinal interleukin-17 promotes thermal hyperalgesia and NMDA NR1 phosphorylation in an inflammatory pain rat model","volume":"154","author":"Meng","year":"2013","journal-title":"Pain"},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/kjm2.12683","article-title":"IL-23\/IL-17 immune axis mediates the imiquimod-induced psoriatic inflammation by activating ACT1\/TRAF6\/TAK1\/NF-\u03baB pathway in macrophages and keratinocytes","volume":"39","author":"Chen","year":"2023","journal-title":"Kaohsiung J. Med. Sci."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"109456","DOI":"10.1016\/j.celrep.2021.109456","article-title":"Prostaglandin E2 amplifies IL-17 production by \u03b3\u03b4 T cells during barrier inflammation","volume":"36","author":"Polese","year":"2021","journal-title":"Cell Rep."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1016\/j.pain.2011.03.035","article-title":"IL-17 induces hyperalgesia via TNF-dependent neutrophil infiltration","volume":"152","author":"McNamee","year":"2011","journal-title":"Pain"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s12964-024-01668-w","article-title":"IL-17 in wound repair: Bridging acute and chronic responses","volume":"22","author":"Mu","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","article-title":"A guide to cancer immunotherapy: From T cell basic science to clinical practice","volume":"20","author":"Waldman","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s13311-015-0401-7","article-title":"Immunotherapy in Peripheral Neuropathies","volume":"13","author":"Muntean","year":"2016","journal-title":"Neurotherapeutics"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"7032","DOI":"10.21037\/jtd-2019-cptn-10","article-title":"Immunotherapy in patients with autoimmune disease","volume":"12","author":"Rakshit","year":"2020","journal-title":"J. Thorac. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Lees, J.G., Duffy, S.S., and Moalem-Taylor, G. (2013). Immunotherapy targeting cytokines in neuropathic pain. Front. Pharmacol., 4.","DOI":"10.3389\/fphar.2013.00142"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"108476","DOI":"10.1016\/j.pharmthera.2023.108476","article-title":"Immunotherapies in chronic pain through modulation of neuroimmune interactions","volume":"248","author":"Zhao","year":"2023","journal-title":"Pharmacol. Ther."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1136\/annrheumdis-2016-209831","article-title":"A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(08)60725-4","article-title":"Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)","volume":"371","author":"Leonardi","year":"2008","journal-title":"Lancet"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1016\/S0140-6736(08)60726-6","article-title":"PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12\/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)","volume":"371","author":"Papp","year":"2008","journal-title":"Lancet"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","article-title":"Efficacy and safety of the anti-IL-12\/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1001\/archdermatol.2007.63","article-title":"Safety and efficacy of ABT-874, a fully human interleukin 12\/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: Results of a randomized, placebo-controlled, phase 2 trial","volume":"144","author":"Kimball","year":"2008","journal-title":"Arch. Dermatol."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/1744666X.2019.1544493","article-title":"Tildrakizumab for the treatment of psoriasis","volume":"15","author":"Sinclair","year":"2019","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","article-title":"Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): Results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials","volume":"392","author":"Gordon","year":"2018","journal-title":"Lancet"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jama.2024.12414","article-title":"Risankizumab for Ulcerative Colitis: Two Randomized Clinical Trials","volume":"332","author":"Louis","year":"2024","journal-title":"JAMA"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1053\/j.gastro.2023.08.038","article-title":"Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study","volume":"165","author":"Allegretti","year":"2023","journal-title":"Gastroenterology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1093\/ecco-jcc\/jjae088","article-title":"Early and Sustained Symptom Control with Mirikizumab in Patients with Ulcerative Colitis in the Phase 3 LUCENT Programme","volume":"18","author":"Danese","year":"2024","journal-title":"J. Crohns. Colitis"},{"key":"ref_173","first-page":"1329","article-title":"Briakinumab for treatment of Crohn\u2019s disease: Results of a randomized trial","volume":"21","author":"Panaccione","year":"2015","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1016\/S0140-6736(22)00467-6","article-title":"Risankizumab as induction therapy for Crohn\u2019s disease: Results from the phase 3 ADVANCE and MOTIVATE induction trials","volume":"399","author":"Panaccione","year":"2022","journal-title":"Lancet"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1016\/S0140-6736(22)00466-4","article-title":"Risankizumab as maintenance therapy for moderately to severely active Crohn\u2019s disease: Results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial","volume":"399","author":"Ferrante","year":"2022","journal-title":"Lancet"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1053\/j.gastro.2022.01.047","article-title":"Guselkumab for the Treatment of Crohn\u2019s Disease: Induction Results From the Phase 2 GALAXI-1 Study","volume":"162","author":"Sandborn","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(23)00318-7","article-title":"Efficacy and safety of 48 weeks of guselkumab for patients with Crohn\u2019s disease: Maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial","volume":"9","author":"Danese","year":"2024","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1053\/j.gastro.2021.10.050","article-title":"Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Crohn\u2019s Disease","volume":"162","author":"Sands","year":"2022","journal-title":"Gastroenterology"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1016\/S0140-6736(24)01762-8","article-title":"Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn\u2019s disease: A phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study","volume":"404","author":"Ferrante","year":"2024","journal-title":"Lancet"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"R1216","DOI":"10.1152\/ajpregu.00540.2013","article-title":"Specific targeting of the IL-23 receptor, using a novel small peptide noncompetitive antagonist, decreases the inflammatory response","volume":"307","author":"Quiniou","year":"2014","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"S439","DOI":"10.14309\/01.ajg.0000592540.43886.35","article-title":"751 Safety, Tolerability, and Pharmacokinetics of PTG-200, an Oral GI-Restricted Peptide Antagonist of IL-23 Receptor, in Normal Healthy Volunteers","volume":"114","author":"Cheng","year":"2019","journal-title":"Am. J. Gastroenterol."}],"container-title":["Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-7737\/14\/4\/347\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:03:18Z","timestamp":1760029398000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-7737\/14\/4\/347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":181,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["biology14040347"],"URL":"https:\/\/doi.org\/10.3390\/biology14040347","relation":{},"ISSN":["2079-7737"],"issn-type":[{"value":"2079-7737","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]}}}